Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives $52.08 Consensus Price Target from Analysts

Posted by George Bondi on Jul 31st, 2026

Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) have earned an average rating of “Moderate Buy” from the thirteen brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $52.5833.

Several research analysts have weighed in on the stock. Wall Street Zen lowered shares of Travere Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Wells Fargo & Company upped their target price on shares of Travere Therapeutics from $50.00 to $65.00 and gave the company an “overweight” rating in a research note on Friday, June 12th. Canaccord Genuity Group increased their price target on shares of Travere Therapeutics from $56.00 to $62.00 and gave the stock a “buy” rating in a research report on Thursday. Guggenheim lifted their price target on Travere Therapeutics from $56.00 to $65.00 and gave the stock a “buy” rating in a research note on Thursday, June 25th. Finally, HC Wainwright lifted their price target on Travere Therapeutics from $57.00 to $67.00 and gave the stock a “buy” rating in a research note on Tuesday, June 2nd.

Read Our Latest Research Report on Travere Therapeutics

Travere Therapeutics Stock Performance

Shares of TVTX opened at $57.28 on Tuesday. The business’s 50 day moving average is $53.33 and its two-hundred day moving average is $40.13. Travere Therapeutics has a 52-week low of $15.03 and a 52-week high of $60.10. The firm has a market cap of $5.33 billion, a price-to-earnings ratio of -249.03 and a beta of 1.10. The company has a quick ratio of 3.08, a current ratio of 3.13 and a debt-to-equity ratio of 3.16.

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last released its quarterly earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. The business had revenue of $127.20 million during the quarter, compared to the consensus estimate of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The business’s quarterly revenue was up 55.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.47) earnings per share. Analysts forecast that Travere Therapeutics will post -0.31 EPS for the current fiscal year.

Insider Activity at Travere Therapeutics

In other news, insider Elizabeth E. Reed sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $45.00, for a total value of $900,000.00. Following the completion of the sale, the insider directly owned 105,211 shares in the company, valued at approximately $4,734,495. The trade was a 15.97% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Jula Inrig sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $45.00, for a total value of $900,000.00. Following the sale, the insider directly owned 111,473 shares in the company, valued at approximately $5,016,285. This represents a 15.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 103,663 shares of company stock worth $4,730,462 over the last quarter. 4.44% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. bought a new stake in Travere Therapeutics during the second quarter valued at $33,000. GAMMA Investing LLC lifted its position in shares of Travere Therapeutics by 53.4% in the 2nd quarter. GAMMA Investing LLC now owns 606 shares of the company’s stock worth $34,000 after buying an additional 211 shares during the last quarter. Fifth Third Bancorp bought a new position in shares of Travere Therapeutics in the 1st quarter worth about $35,000. State of Wyoming acquired a new position in shares of Travere Therapeutics in the 4th quarter valued at about $37,000. Finally, Torren Management LLC acquired a new position in shares of Travere Therapeutics in the 4th quarter valued at about $38,000.

About Travere Therapeutics

(Get Free Report)

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.